HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 37 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Elinzanetant ESMO Calls on EU Research Ministers to Prioritise Cancer Research Funding Within the 10th EU Framework Programme (FP10) AI is impacting cancer care, but also the environment MOST POPULAR New on NCI’s Websites for August 2024 August 16, 2024 Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows September 12, 2018 No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 Hockey Fan Dubbed Hero After Saving Equipment Manager’s Life January 9, 2022 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Olaparib Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against... Scientists find cells in centre of tumours are most likely to... First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield...
